Foghorn therapeutics inc.FHTX.US Overview
FHTX Overall Performance
FHTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
FHTX Key Information
FHTX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
FHTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
FHTX Profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Price of FHTX
FHTX FAQ
When is FHTX's latest earnings report released?
The most recent financial report for Foghorn therapeutics inc. (FHTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FHTX's short-term business performance and financial health. For the latest updates on FHTX's earnings releases, visit this page regularly.
What is the operating profit of FHTX?
According to the latest financial report, Foghorn therapeutics inc. (FHTX) reported an Operating Profit of -18.5M with an Operating Margin of -226.92% this period, representing a growth of 22.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is FHTX's revenue growth?
In the latest financial report, Foghorn therapeutics inc. (FHTX) announced revenue of 8.15M, with a Year-Over-Year growth rate of 4.42%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does FHTX have?
As of the end of the reporting period, Foghorn therapeutics inc. (FHTX) had total debt of 22.53M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does FHTX have?
At the end of the period, Foghorn therapeutics inc. (FHTX) held Total Cash and Cash Equivalents of 92.58M, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does FHTX go with three margins increasing?
In the latest report, Foghorn therapeutics inc. (FHTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -226.92%%, and net margin of -194.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess FHTX's profit trajectory and future growth potential.
Is FHTX's EPS continuing to grow?
According to the past four quarterly reports, Foghorn therapeutics inc. (FHTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of FHTX?
Foghorn therapeutics inc. (FHTX)'s Free Cash Flow (FCF) for the period is -18.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 11.51% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.